Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

339 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab.
Plasencia Ch, Pascual-Salcedo D, Alcocer P, Bonilla MG, Villalba A, Peiteado D, Arribas F, Díez J, Lopez-Casla MT, Martín-Mola E, Balsa A. Plasencia Ch, et al. Among authors: balsa a. Ann Rheum Dis. 2013 Nov;72(11):1888-90. doi: 10.1136/annrheumdis-2013-203353. Epub 2013 Jun 5. Ann Rheum Dis. 2013. PMID: 23740237 No abstract available.
Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars.
Ruiz-Argüello MB, Maguregui A, Ruiz Del Agua A, Pascual-Salcedo D, Martínez-Feito A, Jurado T, Plasencia C, Balsa A, Llinares-Tello F, Rosas J, Torres N, Martínez A, Nagore D. Ruiz-Argüello MB, et al. Among authors: balsa a. Ann Rheum Dis. 2016 Sep;75(9):1693-6. doi: 10.1136/annrheumdis-2015-208684. Epub 2016 Mar 10. Ann Rheum Dis. 2016. PMID: 26965981
Infectious complications of biologic agents.
Martin-Mola E, Balsa A. Martin-Mola E, et al. Among authors: balsa a. Rheum Dis Clin North Am. 2009 Feb;35(1):183-99. doi: 10.1016/j.rdc.2009.03.009. Rheum Dis Clin North Am. 2009. PMID: 19481004 Review.
Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study.
Balsa A, Tovar Beltrán JV, Cáliz Cáliz R, Mateo Bernardo I, García-Vicuña R, Rodríguez-Gómez M, Belmonte Serrano MA, Marras C, Loza Cortina E, Pérez-Pampin E, Vila V. Balsa A, et al. Rheumatol Int. 2015 Sep;35(9):1525-34. doi: 10.1007/s00296-015-3237-x. Epub 2015 Mar 13. Rheumatol Int. 2015. PMID: 25773655
339 results